BridgeBio Pharma LLC - 10 Oct 2025 Form 4 Insider Report for BridgeBio Oncology Therapeutics, Inc. (HLXB)

Reporting relationship: 10%+ Owner
Issuer ticker: HLXB
Reported as of: 10 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Oct 2025, 17:54:33 UTC
Prior SEC filing: 18 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Neil Kumar, Chief Executive Officer of BridgeBio Pharma LLC

Key filing fact

BridgeBio Pharma LLC filed Form 4 for BridgeBio Oncology Therapeutics, Inc. (HLXB) on 16 Oct 2025.

Key facts

This page summarizes BridgeBio Pharma LLC's Form 4 filing for BridgeBio Oncology Therapeutics, Inc. (HLXB).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 16 Oct 2025, 17:54.

Change

Previous filing in this sequence was filed on 18 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0002076615 Primary reporting owner

BridgeBio Pharma LLC

Relationship: 10%+ Owner
Address: C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DRIVE, SUITE 250, PALO ALTO
Signature: /s/ Neil Kumar, Chief Executive Officer of BridgeBio Pharma LLC
Signature date: 16 Oct 2025

CIK 0001743881

BridgeBio Pharma, Inc.

Relationship: 10%+ Owner
Address: 3160 PORTER DR., SUITE 250, PALO ALTO
Signature: /s/ Neil Kumar, Chief Executive Officer of BridgeBio Pharma, Inc.
Signature date: 16 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBOT transaction

Common Stock

Other

Transaction value
Shares: +784,720
Change %: +5.7%
Price
Shares after: 14,589,846
Date: 10 Oct 2025
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Shares issued pursuant to an amendment to the Transition Services Agreement dated August 11, 2025 in exchange for additional financial and accounting support services provided through December 31, 2025.

Footnote F2

Shares are held by BridgeBio Pharma LLC ("BBIO LLC"). Voting and investment power over the shares held by BBIO LLC is exercised by its parent entity, BridgeBio Pharma, Inc. ("BBIO"). The board of directors of BBIO consists of Neil Kumar, Ph.D., Eric Aguiar, M.D., Jennifer E. Cook, Douglas A. Dachille, Ronald J. Daniels, Andrea J. Ellis, Fred Hassan, Charles Homcy, M.D., Andrew W. Lo, Ph.D., Frank P. McCormick, Ph.D., F.R.S., D.Sc., James C. Momtazee, Ali J. Satvat, Randal W. Scott, Ph.D., and Hannah A. Valantine, M.D. (each a BBIO director, and collectively, the "BBIO Directors"). None of the members of the board of directors of BBIO or BBIO LLC has individual voting or investment power with respect to such shares. Each of BBIO and the BBIO Directors disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its, his, or her pecuniary interest therein, if any.

Footnote F3

(Continued from Footnote 2) This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.